Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomod-ulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.

Sagris, M., Theofilis, P., Antonopoulos, A. S., Tsioufis, C., Oikonomou, E., Antoniades, C., Crea, F., Kaski, J. C., Tousoulis, D., Inflammatory mechanisms in covid-19 and atherosclerosis: Current pharmaceutical perspectives, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2021; 22 (12): 6607-N/A. [doi:10.3390/ijms22126607] [http://hdl.handle.net/10807/203999]

Inflammatory mechanisms in covid-19 and atherosclerosis: Current pharmaceutical perspectives

Crea, Filippo;
2021

Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomod-ulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.
2021
Inglese
Sagris, M., Theofilis, P., Antonopoulos, A. S., Tsioufis, C., Oikonomou, E., Antoniades, C., Crea, F., Kaski, J. C., Tousoulis, D., Inflammatory mechanisms in covid-19 and atherosclerosis: Current pharmaceutical perspectives, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2021; 22 (12): 6607-N/A. [doi:10.3390/ijms22126607] [http://hdl.handle.net/10807/203999]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/203999
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 49
social impact